Corporate Presentation December 2019 D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 1
Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” "will,” “would” and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this presentation. These forward-looking statements include, but are not limited to, statements regarding the development of our gene therapies, the success of our collaborations, and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with collaboration arrangements, our and our collaborators’ clinical development activities, regulatory oversight, development of product candidates, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading "Risk Factors" in uniQure’s Quarterly Report on Form 10-Q filed on October 28, 2019. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future. D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 2
Investment highlights • Full patient enrollment in hemophilia B pivotal study, with potential to be first/best-in-class gene therapy • First ever gene therapy for Huntington’s disease recently initiated Phase I/II clinical development • Strong pipeline of other candidates including in Hemophilia A, Fabry disease, and SCA3 • Global commercial rights retained for all core programs • Leadership in large-scale, cGMP manufacturing of AAV gene therapies • Robust portfolio of enabling technologies and intellectual property developed over two decades D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 3
Our proprietary pipeline D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 4 *Collaboration with Bristol-Myers Squibb
Leading the way in AAV manufacturing Large-scale AAV Manufacturing • Based in Lexington, MA, expanded to 80,000 ft 2 Proprietary 3 rd generation insect cell, baculovirus • • Demonstrated 500L stirred-tank production • Scalable up to 2 x 2,000L • Strong intellectual property position Potential Benefits • Control and flexibility • Consistent process from small-scale to large-scale • Highly scalable, cost-effective • High-volume capacity • Consistent, stable, high-quality product D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 5
Leveraging AAV5: a potentially best-in-class vector AAV5 – Clinically demonstrated tolerability and clinical effects AAV5 Vector observed to date • Long-term follow-up data demonstrating safety and tolerability • 25 patients have received AAV5 across 4 clinical studies 1 • Observed clinical effects in the liver and brain • Low avidity of pre-existing neutralizing antibodies (NAbs) • Favorable immunogenicity profile for systemic, intravenous delivery • No confirmed T-cell-mediated immune responses to capsid 1 uniQure clinical trials in Hemophilia B, Sanfilippo B and Acute Intermittent Porphyria D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 6
Hemophilia B Etranacogene dezaparvovec (AMT-061) D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 7
Etranacogene dezaparvovec (AMT-061) Key Treatment Features • Demonstrated ability to increase FIX activity to therapeutic levels • No bleeding events post-treatment • No replacement therapy for bleeds outside surgery • No requirement of immunosuppression • No exclusion of patients with pre-existing NAbs Key Safety Features • Well-tolerated with no serious adverse events related to treatment • No inhibitor development D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 8
AMT-060: sustained dose-dependent increases in FIX activity Cohort 1 Cohort 2 Mean FIX activity (95% CI): Mean FIX activity (95% CI): 5.1 (1.6 – 8.6) 7.5 (4.2 – 10.7) 40 40 6 (11.1) 7 (7.1) 8 (8.5) 9 (3.9) 10 (6.7) 1 (7.1) 2 (5.3) 3* (1.3) 4* (8.2) 5* (3.5) 30 30 FIX activity (IU/dL) FIX activity (IU/dL) 20 20 10 10 0 0 0 20 40 60 80 100 120 140 160 180 200 220 0 20 40 60 80 100 120 140 160 180 200 220 Weeks following AMT-060 treatment Values in parentheses represent mean FIX activity over time. Only values at least 10 days after last FIX concentrate administration are included. FIX prophylaxis was continued after AMT-060 and tapered between Weeks 6 and 12. *Patients 3, 4 and 5 retrospectively tested positive for AAV5 neutralizing antibodies using the luciferase-based assay. Dashed line indicates sample collection occurred after the data cut (09Oct2019). Values after the data cut (Patient 9 4, year 3.5; Patient 10, year 4) are not included in calculations of mean FIX activity. FIX, factor IX; CI, confidence interval; IU, international units
10 Etranacogene dezaparvovec: phase 2b sustained FIX activity in the functionally curative range Mean FIX activity at 1 year: 41% of normal FIX activity measured by a one stage clotting assay conducted in a central lab. aPTT, activated partial thromboplastin time D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 10
Etranacogene dezaparvovec (EtranaDez): HOPE-B Phase III pivotal study • Achieved enrollment of 62 patients with severe and moderately-severe Hemophilia B • Open label, single-dose, multi-center, multi-national trial • Patients with AAV5 neutralizing antibodies not excluded • Patients serve as their own control; 6-month lead-in to establish baseline • Study objectives: • Increase FIX activity • Reduce frequency of bleeding episodes • Decrease use of FIX replacement therapy • Assess efficacy and safety D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 11
Huntington’s Disease AMT-130 D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 12
Executing in Huntington’s Disease Target product profile • One-time administration of disease-modifying therapy Proprietary miQURE TM silencing platform • Huntington’s AMT-130 • Strong mutant HTT knockdown in deep structures and cortex • Targets full length HTT protein aggregates and highly toxic HTT • No treatments available exon1 protein fragments • Strong preclinical data • Potential to be first to market • Near-term goal: Initiate dosing of Phase I/II D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 13
AMT-130: goal of clinical treatment Motor diagnosis Premanifest Manifest 100 AMT-130 ← Function (%) Slow or halt disease progression I II III IV V 0 Presymptomatic Prodromal Early Moderate Advanced Adapted from Ross CA, et al. Nat Rev Neurol 2014;10:204-16 D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 14
Huntington’s disease: patient prevalence CAG-repeat length • Patient population 1 : & age of disease onset • ~25,000 patients in United States • ~25,000 patients in Europe Age of onset • Underreported due to lack of treatment options • Disease stage prevalence 2 : • 30.5% Early stage • 35.5% Middle stage • 34.0% Late stage CAG-repeat length 1 Neuroepidemiology 2016;46:144 – 153 2 Journal of Medical Economics. 2013 Aug;16(8):1043-50 The Lancet 2007;369(9557)218-228 D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 15
Huntington’s disease: expected progression of brain pathology Somatomotor • The striatum is the primary site of cortex Frontal Somatosensory lobe pathology cortex 2 Parietal 3 • Premanifest stage: atrophy 3 lobe spreads and cortical thinning occurs 1 Occipital lobe • Motor symptoms manifest as atrophy increases The shading and arrows indicate the progression of pathology. Darker shading represents earlier onset. 1. McColgan P, Tabrizi SJ. Eur J Neurol. 2018;25(1):24-34; 2.Tabrizi SJ, et al. Lancet Neurol 2009;8(9):791-801; Figure adapted from Brundin P, et al. Nat Rev Mol Cell Biol 2010;11:301-7. 3. Nopoulos PC, et al. Neurobiol Dis 2010;40(3):544-54 D E L I V E R I N G G E N E T H E R A P Y T O P A T I E N T S D E C E M B E R 2 0 1 9 | 16
Recommend
More recommend
